| 42.975 0.005 (0.01%) | 06-21 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 50.25 | 1-year : | 58.7 |
| Resists | First : | 43.02 | Second : | 50.25 |
| Pivot price | 42.8 |
|||
| Supports | First : | 42.47 | Second : | 42.13 |
| MAs | MA(5) : | 42.85 |
MA(20) : | 42.76 |
| MA(100) : | 42.36  |
MA(250) : | 39.64 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 88 |
D(3) : | 86.2 |
| RSI | RSI(14): 64.9 |
|||
| 52-week | High : | 45.75 | Low : | 32.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TARO ] has closed It is unclear right now based on current values. 62.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 42.98 - 43.13 | 43.13 - 43.27 |
| Low: | 42.5 - 42.7 | 42.7 - 42.88 |
| Close: | 42.67 - 42.94 | 42.94 - 43.19 |
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
Wed, 29 Oct 2025
Taro Pharma Beats Investor Suit Over $43-Per-Share Buyout - Law360
Tue, 28 Oct 2025
Sun Pharma Defeats Taro Investor Suit Over Take-Private Deal - Bloomberg Law News
Sun, 26 Oct 2025
Taro to Announce Results for Quarter Ended June 30, 2013 - AOL.com
Fri, 25 Jul 2025
Sun Pharma Agrees To Rs 1,654 Cr Settlement In U.S. Pricing Row - Medical Dialogues
Fri, 25 Jul 2025
Sun Pharma, Taro agree to $200M settlement in generics price-fixing litigation - Fierce Pharma
Thu, 24 Jul 2025
Sun Pharma subsidiaries agree to pay $200 million to settle US generic drug pricing antitrust case - CNBC TV18
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 38 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 78.4 (%) |
| Held by Institutions | 13 (%) |
| Shares Short | 74 (K) |
| Shares Short P.Month | 47 (K) |
| EPS | 1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 47.7 |
| Profit Margin | 8.5 % |
| Operating Margin | 5.9 % |
| Return on Assets (ttm) | 0.2 % |
| Return on Equity (ttm) | 3 % |
| Qtrly Rev. Growth | 12.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 16.74 |
| EBITDA (p.s.) | 1.02 |
| Qtrly Earnings Growth | 118 % |
| Operating Cash Flow | 125 (M) |
| Levered Free Cash Flow | 21 (M) |
| PE Ratio | 30.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.9 |
| Price to Sales | 2.56 |
| Price to Cash Flow | 12.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|